MedPath

Queen's University Belfast

🇧🇪Belgium
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

132

Active:17
Completed:88

Trial Phases

5 Phases

Phase 1:5
Phase 2:4
Phase 3:1
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (105 trials with phase data)• Click on a phase to view related trials

Not Applicable
93 (88.6%)
Phase 1
5 (4.8%)
Phase 2
4 (3.8%)
Phase 4
2 (1.9%)
Phase 3
1 (1.0%)

Feasibility of a Behavioural Activation Protocol to Support People With Parkinson's Enhanced by VR

Not Applicable
Completed
Conditions
Parkinson Disease
First Posted Date
2025-06-26
Last Posted Date
2025-06-26
Lead Sponsor
Queen's University, Belfast
Target Recruit Count
13
Registration Number
NCT07038603
Locations
🇬🇧

Marie Curie, Belfast, United Kingdom

Treatment of Retinal Detachment in People Who Have Not Had Cataract Surgery With Vitrectomy vs Vitrectomy and Cataract Removal

Phase 3
Recruiting
Conditions
Rhegmatogenous Retinal Detachment
First Posted Date
2025-05-30
Last Posted Date
2025-05-30
Lead Sponsor
Queen's University, Belfast
Target Recruit Count
276
Registration Number
NCT06997874
Locations
🇬🇧

Buckinghamshire Healthcare NHS Trust, Aylesbury, United Kingdom

🇬🇧

Belfast Health and Social Care Trust, Belfast, United Kingdom

🇬🇧

Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom

and more 24 locations

Determining the Effect of Food Ordering on Blood Glucose In Gestational Diabetes Mellitus (DEFI-GDM)

Not Applicable
Not yet recruiting
Conditions
Gestational Diabetes Mellitus (GDM)
First Posted Date
2025-03-26
Last Posted Date
2025-03-26
Lead Sponsor
Queen's University, Belfast
Target Recruit Count
35
Registration Number
NCT06896799
Locations
🇬🇧

Centre for Public Health, Institute of Clinical Sciences A, Belfast, United Kingdom

Dissecting the Roles of High-quality Diets and Ultra Processed Foods on Cardiometabolic Health

Not Applicable
Not yet recruiting
Conditions
Cardiometabolic Risk Factors
First Posted Date
2024-12-27
Last Posted Date
2025-01-03
Lead Sponsor
Queen's University, Belfast
Target Recruit Count
330
Registration Number
NCT06749327
Locations
🇮🇪

University College Dublin, Dublin, Ireland

🇬🇧

Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom

Virtual Reality and Post Traumatic Stress

Not Applicable
Conditions
PTSD - Post Traumatic Stress Disorder
First Posted Date
2024-11-12
Last Posted Date
2025-06-27
Lead Sponsor
Queen's University, Belfast
Target Recruit Count
15
Registration Number
NCT06684977
Locations
🇬🇧

South Eastern Health and Social Care Trust (Regional Trauma Network), Belfast, Dundonald, United Kingdom

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 21
  • Next

News

Iridex Enrolls First Patient in DAME Trial Testing MicroPulse Laser as Adjunct to Anti-VEGF Therapy for Severe Diabetic Macular Edema

Iridex Corporation has enrolled the first patient in the independent DAME trial, which will evaluate whether adding subthreshold MicroPulse laser treatment to anti-VEGF therapy can reduce injection burden for severe diabetic macular edema patients.

Weight Loss Injections Show Promising Anti-Cancer Effects Beyond Weight Reduction

Research presented at the European Congress on Obesity suggests weight loss injections may reduce obesity-related cancer risk by nearly 50%, potentially through anti-inflammatory mechanisms beyond simple weight reduction.

Belfast-Based Amply Discovery Secures $1.75M to Accelerate AI-Driven Drug Development for Cancer and Antimicrobial Resistance

Belfast biotech startup Amply Discovery has raised $1.75 million in seed funding to advance its AI-powered drug discovery platform targeting aggressive cancers and antimicrobial resistance.

Semaglutide Drugs Ozempic and Wegovy Linked to Increased Risk of Blinding Eye Condition in New Study

A Harvard-led study found patients prescribed semaglutide (Ozempic/Wegovy) were 4-7 times more likely to develop NAION, a rare eye condition causing permanent vision loss.

© Copyright 2025. All Rights Reserved by MedPath